Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;113:1424-1433
Published online before print March 13, 2006, doi: 10.1161/CIRCULATIONAHA.105.584102
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
113/11/1424    most recent
CIRCULATIONAHA.105.584102v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levy, W. C.
Right arrow Articles by Packer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levy, W. C.
Right arrow Articles by Packer, M.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Heart Failure
Related Collections
Right arrow Health policy and outcome research
Right arrow Chronic ischemic heart disease
Right arrow Epidemiology
Right arrow Congestive
Right arrow Cardiovascular Pharmacology
Right arrow Pacemaker

(Circulation. 2006;113:1424-1433.)
© 2006 American Heart Association, Inc.


Heart Failure

The Seattle Heart Failure Model

Prediction of Survival in Heart Failure

Wayne C. Levy, MD; Dariush Mozaffarian, MD, MPH; David T. Linker, MD; Santosh C. Sutradhar, PhD; Stefan D. Anker, MD; Anne B. Cropp, PharmD; Inder Anand, MD; Aldo Maggioni, MD; Paul Burton, MBBS, PhD; Mark D. Sullivan, MD, PhD; Bertram Pitt, MD; Philip A. Poole-Wilson, MD; Douglas L. Mann, MD; Milton Packer, MD

From the University of Washington, Seattle (W.C.L., D.T.L., M.D.S.); Channing Laboratory, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (D.M.); Merck Research Laboratories, Blue Bell, Pa (S.C.S.); Imperial College School of Medicine, London, UK (S.D.A., P.A.P.-W.); Pfizer Laboratories, Groton, Conn (A.B.C.); University of Minnesota, Minneapolis (I.A.); Italian Association of Hospital Cardiologists Research Center, Florence, Italy (A.M.); Amgen Inc, Thousand Oaks, Calif (P.B.); University of Michigan, Ann Arbor (B.P.); Baylor College of Medicine and Houston Veterans Affairs, Houston, Tex (D.L.M.); and University of Texas Southwestern Medical Center at Dallas (M.P.).

Correspondence to Wayne C. Levy, MD, Division of Cardiology, University of Washington, Box 356422, 1959 NE Pacific St, Seattle, WA 98177. E-mail levywc{at}u.washington.edu

Received August 30, 2005; revision received December 12, 2005; accepted January 13, 2006.

Background— Heart failure has an annual mortality rate ranging from 5% to 75%. The purpose of the study was to develop and validate a multivariate risk model to predict 1-, 2-, and 3-year survival in heart failure patients with the use of easily obtainable characteristics relating to clinical status, therapy (pharmacological as well as devices), and laboratory parameters.

Methods and Results— The Seattle Heart Failure Model was derived in a cohort of 1125 heart failure patients with the use of a multivariate Cox model. For medications and devices not available in the derivation database, hazard ratios were estimated from published literature. The model was prospectively validated in 5 additional cohorts totaling 9942 heart failure patients and 17 307 person-years of follow-up. The accuracy of the model was excellent, with predicted versus actual 1-year survival rates of 73.4% versus 74.3% in the derivation cohort and 90.5% versus 88.5%, 86.5% versus 86.5%, 83.8% versus 83.3%, 90.9% versus 91.0%, and 89.6% versus 86.7% in the 5 validation cohorts. For the lowest score, the 2-year survival was 92.8% compared with 88.7%, 77.8%, 58.1%, 29.5%, and 10.8% for scores of 0, 1, 2, 3, and 4, respectively. The overall receiver operating characteristic area under the curve was 0.729 (95% CI, 0.714 to 0.744). The model also allowed estimation of the benefit of adding medications or devices to an individual patient’s therapeutic regimen.

Conclusions— The Seattle Heart Failure Model provides an accurate estimate of 1-, 2-, and 3-year survival with the use of easily obtained clinical, pharmacological, device, and laboratory characteristics.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
CirculationHome page
B. Heidecker, E. K. Kasper, I. S. Wittstein, H. C. Champion, E. Breton, S. D. Russell, M. M. Kittleson, K. L. Baughman, and J. M. Hare
Transcriptomic Biomarkers for Individual Risk Assessment in New-Onset Heart Failure
Circulation, July 15, 2008; 118(3): 238 - 246.
[Abstract] [Full Text] [PDF]


Home page
Circ Heart FailHome page
P. J. Hauptman
Does It Matter Why and How Patients With Heart Failure Die?: A Debate That Lives On
Circ Heart Fail, July 1, 2008; 1(2): 89 - 90.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. J. Sehnert, S. E. Daniels, M. Elashoff, J. A. Wingrove, C. R. Burrow, B. Horne, J. B. Muhlestein, M. Donahue, S. B. Liggett, J. L. Anderson, et al.
Lack of Association Between Adrenergic Receptor Genotypes and Survival in Heart Failure Patients Treated With Carvedilol or Metoprolol
J. Am. Coll. Cardiol., June 23, 2008; (2008) j.jacc.2008.05.022v1.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W.H. W. Tang
The ongoing search for a stratified medicine approach in heart failure.
J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2310 - 2312.
[Full Text] [PDF]


Home page
JAMAHome page
L. A. Allen, J. E. Yager, M. J. Funk, W. C. Levy, J. A. Tulsky, M. T. Bowers, G. C. Dodson, C. M. O'Connor, and G. M. Felker
Discordance Between Patient-Predicted and Model-Predicted Life Expectancy Among Ambulatory Patients With Heart Failure
JAMA, June 4, 2008; 299(21): 2533 - 2542.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
C. W. Yancy
Predicting Life Expectancy in Heart Failure
JAMA, June 4, 2008; 299(21): 2566 - 2567.
[Full Text] [PDF]


Home page
JNMHome page
S. Kasama, T. Toyama, H. Sumino, M. Nakazawa, N. Matsumoto, Y. Sato, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, et al.
Prognostic Value of Serial Cardiac 123I-MIBG Imaging in Patients with Stabilized Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction
J. Nucl. Med., June 1, 2008; 49(6): 907 - 914.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. Mark Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2085 - 2105.
[Full Text] [PDF]


Home page
CirculationHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation, May 27, 2008; 117(21): 2820 - 2840.
[Full Text] [PDF]


Home page
CirculationHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation, May 27, 2008; 117(21): e350 - e408.
[Full Text] [PDF]


Home page
Circ Heart FailHome page
I. S. Anand, T. S. Rector, M. Kuskowski, S. Thomas, N.J. Holwerda, and J. N. Cohn
Effect of Baseline and Changes in Systolic Blood Pressure Over Time on the Effectiveness of Valsartan in the Valsartan Heart Failure Trial
Circ Heart Fail, May 1, 2008; 1(1): 34 - 42.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. J. Thune, J. Signorovitch, L. Kober, E. J. Velazquez, J. J.V. McMurray, R. M. Califf, A. P. Maggioni, J. L. Rouleau, J. Howlett, S. Zelenkofske, et al.
Response to The J-Point Revisited
Hypertension, May 1, 2008; 51(5): e35 - e35.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. C. Levy
Anemia in heart failure: marker or mediator of adverse prognosis?
J. Am. Coll. Cardiol., February 5, 2008; 51(5): 577 - 578.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
N. E. Goldstein and D. Fischberg
Update in Palliative Medicine
Ann Intern Med, January 15, 2008; 148(2): 135 - 140.
[Full Text] [PDF]


Home page
HypertensionHome page
J. J. Thune, J. Signorovitch, L. Kober, E. J. Velazquez, J. J.V. McMurray, R. M. Califf, A. P. Maggioni, J. L. Rouleau, J. Howlett, S. Zelenkofske, et al.
Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction
Hypertension, January 1, 2008; 51(1): 48 - 54.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
R. S. Braithwaite, J. Concato, C. C. Chang, M. S. Roberts, and A. C. Justice
A Framework for Tailoring Clinical Guidelines to Comorbidity at the Point of Care
Arch Intern Med, November 26, 2007; 167(21): 2361 - 2365.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Sandek, J. Bauditz, A. Swidsinski, S. Buhner, J. Weber-Eibel, S. von Haehling, W. Schroedl, T. Karhausen, W. Doehner, M. Rauchhaus, et al.
Altered Intestinal Function in Patients With Chronic Heart Failure
J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1561 - 1569.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
P. J. Hauptman, S. J. Goodlin, M. Lopatin, M. R. Costanzo, G. C. Fonarow, C. W. Yancy, and for the ADHERE Scientific Advisory Committee and A
Characteristics of Patients Hospitalized With Acute Decompensated Heart Failure Who Are Referred for Hospice Care
Arch Intern Med, October 8, 2007; 167(18): 1990 - 1997.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. J. Wang
Significance of Circulating Troponins in Heart Failure: If These Walls Could Talk
Circulation, September 11, 2007; 116(11): 1217 - 1220.
[Full Text] [PDF]


Home page
HeartHome page
A. Mosterd and A. W Hoes
Clinical epidemiology of heart failure
Heart, September 1, 2007; 93(9): 1137 - 1146.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
L. W. Stevenson and G. Couper
On the Fledgling Field of Mechanical Circulatory Support
J. Am. Coll. Cardiol., August 21, 2007; 50(8): 748 - 751.
[Full Text] [PDF]


Home page
CirculationHome page
K. Lietz, J. W. Long, A. G. Kfoury, M. S. Slaughter, M. A. Silver, C. A. Milano, J. G. Rogers, Y. Naka, D. Mancini, and L. W. Miller
Outcomes of Left Ventricular Assist Device Implantation as Destination Therapy in the Post-REMATCH Era: Implications for Patient Selection
Circulation, July 31, 2007; 116(5): 497 - 505.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. R. Goldberg and M. Jessup
A Time to be Born and a Time to Die
Circulation, July 24, 2007; 116(4): 360 - 362.
[Full Text] [PDF]


Home page
CirculationHome page
D. Mozaffarian, S. D. Anker, I. Anand, D. T. Linker, M. D. Sullivan, J. G.F. Cleland, P. E. Carson, A. P. Maggioni, D. L. Mann, B. Pitt, et al.
Prediction of Mode of Death in Heart Failure: The Seattle Heart Failure Model
Circulation, July 24, 2007; 116(4): 392 - 398.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. M. Felker, L. A. Allen, S. J. Pocock, L. K. Shaw, J. J.V. McMurray, M. A. Pfeffer, K. Swedberg, D. Wang, S. Yusuf, E. L. Michelson, et al.
Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure: Data From the CHARM Program and the Duke Databank
J. Am. Coll. Cardiol., July 3, 2007; 50(1): 40 - 47.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. H. Le Jemtel and S. Jelic
Seek and Treat Obstructive Sleep Apnea in Heart Failure
J. Am. Coll. Cardiol., April 17, 2007; 49(15): 1632 - 1633.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Butler and A. Leon
The Elusive Scourge of Sudden Cardiac Death: Is Rational Decision Making Possible? Should There Be Standards of Risks and Predictions in Medicine?
J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1434 - 1435.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
I. Goldenberg, A. J. Moss, S. McNitt, W. Zareba, W. J. Hall, M. L. Andrews, and for the MADIT-II Investigators
Inverse Relationship of Blood Pressure Levels to Sudden Cardiac Mortality and Benefit of the Implantable Cardioverter-Defibrillator in Patients With Ischemic Left Ventricular Dysfunction
J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1427 - 1433.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
B. C. Huynh, A. Rovner, and M. W. Rich
Long-term Survival in Elderly Patients Hospitalized for Heart Failure: 14-Year Follow-up From a Prospective Randomized Trial.
Arch Intern Med, September 25, 2006; 166(17): 1892 - 1898.
[Abstract] [Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
Tool for Predicting Survival in Heart Failure
Journal Watch Cardiology, May 4, 2006; 2006(504): 4 - 4.
[Full Text]